1-4 of 4
David I. Marks, MD, PhD
Close
Sort by
Journal Articles

Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia

Hagop M. Kantarjian, MD, Yun Su, MD MPH, Elias J. Jabbour, MD, Helen Bhattacharyya, PhD, Eric Yan, PhD, Mark Shapiro, MD PhD, Joseph C. Cappelleri, PhD MPH, MS, David I. Marks, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1599.
https://doi.org/10.1182/blood.V128.22.1599.1599
Published: 2016
Journal Articles

Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia

Partow Kebriaei, MD, Claudio Anasetti, MD, Mei-Jie Zhang, PhD, Hai-Lin Wang, MPH, Ibrahim Aldoss, MD, Marcos de Lima, MD, H. Jean Khoury, MD, Brenda M. Sandmaier, MD, Mary M. Horowitz, MD MS, Andrew Artz, MD MS, Nelli Bejanyan, MD, Stefan O. Ciurea, MD, Hillard M. Lazarus, MD, Robert Peter Gale, MD PhD, Mark Litzow, MD, Christopher N. Bredeson, MD MSc, FRCPC, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Michael A Pulsipher, MD, Jaap Jan Boelens, MDPhD, Joseph Alvarnas, MD, Richard E. Champlin, MD, Stephen J. Forman, MD, Vinod Pullarkat, MD, Daniel Weisdorf, MD, David I. Marks, MD PhD
Journal: Blood
Blood (2016) 128 (22): 679.
https://doi.org/10.1182/blood.V128.22.679.679
Published: 2016
Journal Articles

Comparison of Outcomes for Non-Myeloablative (NMA) and Myeloablative (MA) Conditioning for Adults with Acute Lymphoblastic Leukaemia (ALL) in First and Second Complete Remission (CR): a Center for International Blood and Marrow Transplant Research (CIBMTR) Analyisis.

David I. Marks, MD, PhD, Tao Wang, PhD, Waleska S. Peréz, MPH, Donald W. Bunjes, MD, PhD, John F. DiPersio, MD, PhD, Martin S. Tallman, MD, Daniel J. Weisdorf, MD
Journal: Blood
Blood (2009) 114 (22): 872.
https://doi.org/10.1182/blood.V114.22.872.872
Published: 2009
Journal Articles

Unrelated Donor (URD) Hematopoietic Stem Cell Transplantation (HCT) for Adults with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia (ALL) in First Complete Remission (CR1): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis.

David I. Marks, MD, PhD, Waleska S. Pérez, MPH, Vincent He, MS, Mei-Jie Zhang, PhD, Armand Keating, MD, Martin Tallman, MD, Jorge Sierra, MD, Daniel Weisdorf, MD
Journal: Blood
Blood (2007) 110 (11): 3055.
https://doi.org/10.1182/blood.V110.11.3055.3055
Published: 2007